Ching-Hon Pui
裴正宏
MD
Department Chair Emeritus, Oncology; Fahad Nassar Al-Rashid Chair of Leukemia Research; Member, St. Jude Children's Research Hospital肿瘤学系荣誉主任，白血病研究教授
👥Biography 个人简介
Ching-Hon Pui, MD is one of the world's foremost authorities on pediatric acute lymphoblastic leukemia (ALL), having spent over four decades at St. Jude Children's Research Hospital transforming it from a uniformly fatal disease to one with cure rates exceeding 90% in children. He pioneered risk-stratified, total-therapy approaches—collectively known as the St. Jude Total Therapy protocols—that systematically replaced cranial irradiation with intrathecal chemotherapy for CNS prophylaxis, dramatically reducing long-term neurocognitive toxicity while maintaining disease control. His work on minimal residual disease (MRD) monitoring established a new paradigm for treatment response assessment and early intensification decisions. Dr. Pui has authored or co-authored more than 1,000 peer-reviewed publications and his protocols have become the global benchmark for pediatric ALL management.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
St. Jude Total Therapy Protocols for Pediatric ALL
Designed and led successive generations of the St. Jude Total Therapy trials (Total XV, XVI) achieving >90% 5-year event-free survival in childhood ALL, and demonstrating that cranial irradiation could be entirely eliminated without compromising CNS control through optimized intrathecal and systemic chemotherapy intensification.
Elimination of Prophylactic Cranial Irradiation
Conducted landmark trials proving that prophylactic cranial irradiation could be replaced by intrathecal chemotherapy in the vast majority of patients, sparing children from radiation-induced neurocognitive sequelae, growth failure, and secondary brain tumors—a change now adopted worldwide.
MRD-Guided Treatment Stratification
Pioneered the use of end-induction and end-consolidation minimal residual disease (MRD) measurement by flow cytometry and PCR to guide treatment intensification and deescalation, establishing MRD as the strongest independent prognostic factor in childhood ALL.
Genomic Subtype Discovery and Risk Classification
Contributed to the identification of novel ALL genomic subtypes including Philadelphia chromosome-like ALL (Ph-like ALL), enabling targeted therapy with tyrosine kinase inhibitors and reclassifying patients previously misassigned to standard-risk groups.
Representative Works 代表性著作
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital
Blood (2004)
Demonstrated 80% 5-year EFS for childhood ALL using MRD-guided risk stratification and intensified CNS-directed chemotherapy without cranial irradiation.
Treating childhood acute lymphoblastic leukemia without cranial irradiation
New England Journal of Medicine (2009)
Landmark trial (Total XV) showing that cranial irradiation could be entirely eliminated in childhood ALL achieving 93.7% 5-year EFS, establishing the modern CNS prophylaxis standard.
Philadelphia chromosome-like acute lymphoblastic leukemia
Nature Reviews Clinical Oncology (2017)
Comprehensive review defining Ph-like ALL as a high-risk genomic subtype with targetable kinase fusions, forming the basis for ongoing clinical trials with TKIs.
Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region
Lancet (2002)
Defined the poor-prognosis features of MLL-rearranged infant and childhood ALL, guiding intensification strategies for this high-risk subset.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 裴正宏 的研究动态
Follow Ching-Hon Pui's research updates
留下邮箱，当我们发布与 Ching-Hon Pui（St. Jude Children's Research Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment